In particular, our recent publication showed that during Alzheimer’s disease (AD) development, plasminogen decreases Aβ42 and Tau deposition, increases choline acetyltransferase (ChAT) levels and decreases acetylcholinesterase (AChE) activity, and thus effectively treats AD in mice and humans17. Here, MAPT is linked to Alzheimer disease.